Further use of protein kinase N beta
AssigneeSilence Therapeutics GmbH
InventorsAnke Klippel-Giese, Jörg Kaufmann
Life of this patent
Estimating the term…
Abstract
The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.
Claims32
A method of treating adenocarcinoma comprising administering to a subject having adenocarcinoma an effective amount of a composition comprising an siRNA molecule or an antisense oligonucleotide that inhibits the activity of protein kinase N beta by causing degradation of a ribonucleic acid encoding protein kinase N beta, wherein protein kinase N beta is up-regulated in adenocarcinoma cells as compared to non-tumor cells of the same lineage.
A method of inhibiting or reducing the metastasis or migration of a tumor cell or a hyperplastic cell comprising administering to a subject a composition comprising an siRNA molecule or an antisense oligonucleotide in an amount effective to inhibit the metastasis or migration of said tumor cell or hyperplastic cell, wherein said siRNA molecule or antisense oligonucleotide molecule inhibits the activity of protein kinase N beta by causing degradation of a ribonucleic acid encoding protein kinase N beta and wherein protein kinase N beta is up-regulated in said tumor cell or hyperplastic cell as compared to non-tumor cells or non-hyperplastic cells of the same lineage.
A method of treating cancer comprising administering to a subject having a cancer an effective amount of a composition comprising an siRNA molecule or an antisense oligonucleotide that inhibits the activity of protein kinase N beta by causing degradation of a ribonucleic acid encoding protein kinase N beta, wherein protein kinase N beta is up-regulated in the cells of said cancer as compared to non-cancer cells of the same lineage.
Dependencies are inferred from the claim text.